Pages that link to "Q46431265"
Jump to navigation
Jump to search
The following pages link to Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections (Q46431265):
Displaying 50 items.
- Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications (Q24646677) (← links)
- Relationship between vancomycin-resistant Staphylococcus aureus, vancomycin-intermediate S. aureus, high vancomycin MIC, and outcome in serious S. aureus infections (Q27011138) (← links)
- Methicillin-resistant Staphylococcus aureus therapy: past, present, and future (Q27011165) (← links)
- Nosocomial methicillin-resistant Staphylococcus aureus (MRSA) bacteremia in Taiwan: mortality analyses and the impact of vancomycin, MIC = 2 mg/L, by the broth microdilution method (Q33596888) (← links)
- Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes (Q33642100) (← links)
- Comparison of commercial antimicrobial susceptibility test methods for testing of Staphylococcus aureus and Enterococci against vancomycin, daptomycin, and linezolid (Q33703519) (← links)
- Clinical characteristics, outcomes, and microbiologic features associated with methicillin-resistant Staphylococcus aureus bacteremia in pediatric patients treated with vancomycin (Q33704710) (← links)
- Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections (Q33881584) (← links)
- Outcomes with daptomycin in the treatment of Staphylococcus aureus infections with a range of vancomycin MICs (Q33997671) (← links)
- Inadequate vancomycin therapy in term and preterm neonates: a retrospective analysis of trough serum concentrations in relation to minimal inhibitory concentrations (Q34014285) (← links)
- High vancomycin minimum inhibitory concentration and clinical outcomes in adults with methicillin-resistant Staphylococcus aureus infections: a meta-analysis (Q34454418) (← links)
- Predicting high vancomycin minimum inhibitory concentration in methicillin-resistant Staphylococcus aureus bloodstream infections (Q34756833) (← links)
- Vancomycin and daptomycin minimum inhibitory concentration distribution and occurrence of heteroresistance among methicillin-resistant Staphylococcus aureus blood isolates in Turkey (Q35064413) (← links)
- Clinical and laboratory characteristics of invasive infections due to methicillin-resistant Staphylococcus aureus isolates demonstrating a vancomycin MIC of 2 micrograms per milliliter: lack of effect of heteroresistant vancomycin-intermediate S. au (Q35066896) (← links)
- Expert Systems in Clinical Microbiology (Q35090146) (← links)
- Prediction of Failure in Vancomycin-Treated Methicillin-Resistant Staphylococcus aureus Bloodstream Infection: a Clinically Useful Risk Stratification Tool (Q35270746) (← links)
- High prevalence of isolates with reduced glycopeptide susceptibility in persistent or recurrent bloodstream infections due to methicillin-resistant Staphylococcus aureus (Q35806306) (← links)
- Bacteriological profile and antimicrobial susceptibility patterns of blood culture isolates among febrile patients in Mekelle Hospital, Northern Ethiopia (Q35811848) (← links)
- Methicillin-resistant Staphylococcus aureus (MRSA) catheter-related bacteraemia in haemodialysis patients (Q35827804) (← links)
- Comparative efficacies of human simulated exposures of tedizolid and linezolid against Staphylococcus aureus in the murine thigh infection model (Q36171683) (← links)
- Effect of reduced vancomycin susceptibility on clinical and economic outcomes in Staphylococcus aureus bacteremia (Q36276932) (← links)
- Derivation and validation of clinical prediction rules for reduced vancomycin susceptibility in Staphylococcus aureus bacteraemia (Q36456630) (← links)
- Healthcare-associated Staphylococcus aureus Bacteremia in Children: Evidence for Reverse Vancomycin Creep and Impact of Vancomycin Trough Values on Outcome (Q36576652) (← links)
- Vancomycin AUC/MIC ratio and 30-day mortality in patients with Staphylococcus aureus bacteremia (Q36757645) (← links)
- Optimizing the detection of methicillin-resistant Staphylococcus aureus with elevated vancomycin minimum inhibitory concentrations within the susceptible range. (Q36981191) (← links)
- Vancomycin MIC Does Not Predict 90-Day Mortality, Readmission, or Recurrence in a Prospective Cohort of Adults with Staphylococcus aureus Bacteremia (Q37203845) (← links)
- Daptomycin Improves Outcomes Regardless of Vancomycin MIC in a Propensity-Matched Analysis of Methicillin-Resistant Staphylococcus aureus Bloodstream Infections (Q37287739) (← links)
- Should higher vancomycin trough levels be targeted for invasive community-acquired methicillin-resistant Staphylococcus aureus infections in children? (Q37358940) (← links)
- Review of question and answer session (Q37533565) (← links)
- Synergistic Effect between Cryptotanshinone and Antibiotics against Clinic Methicillin and Vancomycin-Resistant Staphylococcus aureus. (Q37695643) (← links)
- The quest to identify heterogeneously resistant vancomycin-intermediate Staphylococcus aureus strains (Q37776832) (← links)
- Is vancomycin redundant for serious staphylococcal infection? (Q37815673) (← links)
- Clinical activity of anti-Gram-positive agents against methicillin-resistant Staphylococcus aureus (Q37869254) (← links)
- The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. (Q37981103) (← links)
- Cost-effectiveness of linezolid in methicillin-resistant Staphylococcus aureus skin and skin structure infections (Q38068456) (← links)
- Use of daptomycin to treat infections with methicillin-resistant Staphylococcus aureus isolates having vancomycin minimum inhibitory concentrations of 1.5 to 2 μg/mL. (Q38164663) (← links)
- The Nephrotoxicity of Vancomycin (Q38687487) (← links)
- Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration. (Q38793919) (← links)
- Dosing strategies to optimize currently available anti-MRSA treatment options (Part 1: IV options). (Q38907793) (← links)
- Discrepancy in Vancomycin AUC/MIC Ratio Targeted Attainment Based upon the Susceptibility Testing in Staphylococcus aureus (Q39334338) (← links)
- Staphylococcus aureus Isolates Carrying Panton-Valentine Leucocidin Genes: Their Frequency, Antimicrobial Patterns, and Association With Infectious Disease in Shahrekord City, Southwest Iran (Q40258944) (← links)
- Implementation of an antimicrobial stewardship pathway with daptomycin for optimal treatment of methicillin-resistant Staphylococcus aureus bacteremia (Q40261278) (← links)
- Is vancomycin MIC "creep" method dependent? Analysis of methicillin-resistant Staphylococcus aureus susceptibility trends in blood isolates from North East Scotland from 2006 to 2010. (Q40600332) (← links)
- Are Vancomycin Trough Concentrations of 15 to 20 mg/L Associated With Increased Attainment of an AUC/MIC ≥ 400 in Patients With Presumed MRSA Infection? (Q40716347) (← links)
- Differences in Method-Specific Vancomycin MICs and Induced Daptomycin Resistance in an Infective Endocarditis Patient. (Q40728255) (← links)
- Methicillin Resistant Staphylococcus aureus: Inconsistencies in Vancomycin Susceptibility Testing Methods, Limitations and Advantages of each Method (Q40914477) (← links)
- A mutation of RNA polymerase β' subunit (RpoC) converts heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA) into "slow VISA" (Q41259277) (← links)
- Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods. (Q41428954) (← links)
- Evaluation of vancomycin susceptibility testing for methicillin-resistant Staphylococcus aureus: comparison of Etest and three automated testing methods (Q41429045) (← links)
- In vitro vancomycin susceptibility amongst methicillin resistant Staphylococcus aureus. (Q41672254) (← links)